CURE - Oncology & Cancer News for Patients & Caregivers
WEBChoices About Cancer Treatment During a Tumultuous Time. September 12th 2024. In this Fall issue of CURE, we focus on AYAs with cancer, latest treatments in small cell lung cancer, preparing for a virtual visit and answering common questions about breast cancer.
GO2 For Lung Cancer | Advocacy Groups - Curetoday
WEBGO2 is at the forefront of everything that’s happening in lung cancer. We’re the go-to for one-on-one assistance, supportive connections, screening and treatment information, and finding the best care close to home. We’re the place to go to learn about the latest research and special initiatives that increase survivorship. We’re the source for improving health policies and leading ...
Long-Term Follow-Up Shows Keytruda Continues to Improve
WEBFeb 1, 2021 · Keytruda (pembrolizumab) continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer (NSCLC) after more than five years of follow-up, according to results from the phase 2/3 KEYNOTE-010 study presented at the 2020 World Conference on Lung ...
What Patients with Prostate Cancer Need to Know About
WEBJul 16, 2024 · For patients with prostate cancer undergoing radiation, the side effect burden exists on a spectrum, as one nurse explained to CURE®. “Not one patient experiences everything to their full degree,” Jessica Fox, a radiation oncology nurse with Providence Cancer Institute in Portland, Oregon said during a conversation that was part of the “Speaking Out” video series.
Keytruda Has Received Nearly 40 FDA Approvals. How Does It Work?
WEBJan 25, 2024 · An expert explains how immunotherapy works. The Food and Drug Administration (FDA) recently approved Keytruda (pembrolizumab) plus chemoradiotherapy (CRT) for the treatment of patients with stages 3 to 4A cervical cancer. The first approval of an anti-programmed death receptor-1 (PD-1) therapy in combination with chemoradiotherapy for this ...
Pluvicto Improves Survival Without Progression in Certain Patients …
WEBOct 23, 2023 · Pluvicto improved progression-free survival in certain patients with prostate cancer, recent research showed. Treatment with Pluvicto (177-Lu-PSMA-617) improved the duration of time when a patient’s disease did not progress with a favorable safety profile in patients with metastatic castration-resistant prostate cancer (mCRPC) who were taxane ...
How I Used Turkey Tail Mushrooms Alongside Cancer Treatment
WEBJan 8, 2024 · Turkey tail is a shelf mushroom, named that because of the way they grow on dead and decaying trees like little rows of shelves. Because of its positive effects on the immune system. Studies, such as one published in 2023 in the journal, Cureus, show that use of the mushroom improved outcomes among patients who use it …
20 Inspirational Quotes for Cancer Survivors, Fighters and
WEBAug 26, 2015 · 1. You beat cancer by how you live, why you live, and in the manner in which you live. — Stuart Scott. Live your life by your own terms, not cancer's. 2. Remember how far you've come, not just how far you have to go. You may not be where you want to be, but neither are you where you used to be. It can be …
FDA Approves Opdualag, a New Fixed-Dose Combination
WEBMar 19, 2022 · The Food and Drug Administration (FDA) approved Opdualag, a fixed-dose combination of Opdivo (nivolumab) and relatlimab-rmbw, as a treatment option for children and adults aged 12 years or older with unresectable or metastatic melanoma, a type of skin cancer, according to Bristol Myers Squibb. “ (This) …
How Patients With Cancer Can Best Care For Their Chemo Port
WEBJun 23, 2022 · A port, also known as a port-a-cath, among other names, is a device that is surgically implanted under a patient’s skin, typically on the right side of the chest. This allows cancer teams to draw blood and give treatments such as blood transfusions, intravenous fluids or drugs like antibiotics and chemotherapy without the …